AQST Logo

Aquestive Therapeutics, Inc. (AQST) 

NASDAQ
Market Cap
$337.82M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
550 of 963
Rank in Industry
31 of 59

Largest Insider Buys in Sector

AQST Stock Price History Chart

AQST Stock Performance

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Insider Activity of Aquestive Therapeutics, Inc.

Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $429,899 worth of Aquestive Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $54,873 and sold $951,306 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.

List of Insider Buy and Sell Transactions, Aquestive Therapeutics, Inc.

2024-11-26SaleChief Operating Officer
44
<0.0001%
$4.87$214-11.58%
2024-03-15SaleChief Innovation/Tech Officer
50,000
0.0672%
$6.00$300,000-31.86%
2024-03-08SaleChief Innovation/Tech Officer
25,000
0.0364%
$5.19$129,685-14.55%
2022-06-14PurchaseSVP-Bus. Process & Info. Tech.
5,000
0.0107%
$0.81$4,050+11.38%
2022-06-08PurchaseChief Innovation/Tech Officer
45,871
0.1074%
$0.96$44,036+2.88%
2022-06-08PurchaseSVP-Bus. Process & Info. Tech.
2,293
0.0054%
$0.96$2,201+2.88%
2022-06-08PurchaseGeneral Counsel
13,761
0.0322%
$0.96$13,211+2.88%
2021-02-10Sale
23,460
0.0662%
$6.75$158,355-38.78%
2021-02-09Sale
11,540
0.0328%
$6.75$77,895-38.02%
2021-02-08Sale
40,792
0.1131%
$6.50$265,148-37.03%
2020-08-18Sale
3,000
0.0088%
$8.00$24,000-37.84%
2020-06-04Sale
100,000
0.2958%
$5.11$510,620+2.92%
2020-05-08Sale
80,000
0.2312%
$5.00$400,000+3.69%
2020-04-29Sale
80,000
0.2256%
$4.50$360,000+12.42%
2020-04-27Sale
80,000
0.229%
$4.00$320,000+28.37%
2020-04-14Sale
80,000
0.2445%
$3.85$308,000+42.40%
2020-03-16Purchase
4,000
0.0058%
$0.75$3,000+246.43%
2020-03-16Purchase
28,000
0.0837%
$1.54$43,249+246.43%
2019-08-27Purchase
4,000
0.0166%
$3.99$15,960+14.36%
2019-08-21Purchase
1,800
0.0068%
$3.81$6,858+7.92%

Insider Historical Profitability

1.68%
Schobel Alexander MarkChief Innovation/Tech Officer
984476
1.0797%
$3.7149<0.0001%
Jung CassieChief Operating Officer
0
0%
$3.7101
Kendall Keith J
638964
0.7008%
$3.7161<0.0001%
BRATTON DOUGLAS K
165000
0.181%
$3.7110
Maxwell John T.
150614
0.1652%
$3.7121<0.0001%
Barber Daniel
101959
0.1118%
$3.7120<0.0001%
Wood Theresa
80765
0.0886%
$3.7120<0.0001%
Boyd Peter E.SVP-Bus. Process & Info. Tech.
59532
0.0653%
$3.7150+43.71%
BRAENDER LORI JGeneral Counsel
38761
0.0425%
$3.7140+53.96%
Scibetta James S
31635
0.0347%
$3.7130+13.42%
Marshall Ken W.
1445
0.0016%
$3.7110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bratton Capital Management L P$41.79M10.789.81M0%+$0100
Vr Adviser Llc$23.67M6.15.56MNew+$23.67M1.15
The Vanguard Group$13.81M3.563.24M+71.65%+$5.77M<0.0001
Franklin Templeton Investments$9.46M2.442.22MNew+$9.46M<0.01
Laurion Capital Management LP$6.58M1.71.55MNew+$6.58M0.05
Renaissance Technologies$5.86M1.511.38M+8.2%+$444,324.970.01
BlackRock$5.73M1.481.34M+181.34%+$3.69M<0.0001
Monashee Investment Management LLC$4.26M1.11MNew+$4.26M0.37
Invesco$3.82M0.99897,512New+$3.82M<0.01
Blue Owl Capital Holdings Lp$3.73M0.96875,000New+$3.73M0.31
Qube Research & Technologies$3.62M0.93849,213+1,176.11%+$3.33M<0.01
GHOST TREE CAPITAL LLC$2.99M0.77702,941New+$2.99M0.04
Altium Capital Management Lp$2.83M0.73665,000New+$2.83M0.33
ESSEX INVESTMENT MANAGEMENT CO LLC$2.61M0.67612,949-27.56%-$993,508.780.53
Susquehanna International Group$2.56M0.66601,989+1,473.54%+$2.4M<0.01
Woodline Partners LP$2.56M0.66600,592New+$2.56M0.02
Velan Capital$2.56M0.66600,000New+$2.56M1.39
Geode Capital Management$2.29M0.59538,456+8.8%+$185,598.31<0.0001
Acadian Asset Management$2.27M0.59533,567-3.07%-$72,003.150.01
Goldman Sachs$2.24M0.58526,422+1,626.03%+$2.11M<0.0001
Alyeska Investment Group L P$2.13M0.55500,000New+$2.13M0.01
DAFNA Capital Management, LLC$2.13M0.55500,000New+$2.13M0.05
Millennium Management LLC$2.11M0.54494,445+278.93%+$1.55M<0.01
Bracebridge Capital, LLC$1.83M0.47428,5710%+$00.36
LMR PARTNERS LLP$1.77M0.46414,480New+$1.77M0.04
Stifel$1.66M0.43389,882New+$1.66M<0.01
Janney Montgomery Scott LLC$1.46M0.38341,860New+$1.46M0.01
Hrt Financial Llc$1.22M0.31285,360New+$1.22M0.01
Jane Street Capital$1.12M0.29263,140+68.59%+$456,054.54<0.01
Legato Capital Management Llc$1.06M0.27248,503-27.03%-$392,179.940.13
Latash Investments Llc$1.04M0.27243,1340%+$00.74
Citadel Advisors LLC$955,403.000.25224,273+33.64%+$240,502.57<0.01
Man Group Plc$946,086.000.24222,086New+$946,086.00<0.01
Connor Clark & Lunn Investment Management Ltd$934,640.000.24219,399-16.13%-$179,742.23<0.01
Bridgeway Capital Management$821,567.000.21192,8560%+$00.01
State Street$773,774.000.2181,637+19.86%+$128,226.06<0.0001
Eam Investors$461,119.000.12108,244New+$461,119.000.03
JPMorgan Chase$436,305.000.11102,419+100.6%+$218,806.41<0.0001
Virtu Financial Llc$438,000.000.11102,836+219.66%+$300,981.250.04
Northern Trust$417,140.000.1197,920+7.38%+$28,661.33<0.0001
D. E. Shaw & Co.$405,607.000.1195,213New+$405,607.00<0.0001
Ci Private Wealth Llc$408,163.000.1195,813-50%-$408,163.00<0.0001
Morgan Stanley$395,848.000.192,922+284.53%+$292,905.03<0.0001
Marathon Trading Investment Management Llc$383,400.000.190,000New+$383,400.000.08
Cahill Wealth Management Llc$367,268.000.186,213New+$367,268.000.27
Advisor Group Holdings Inc$365,422.000.0985,780New+$365,422.00<0.01
Diametric Capital Lp$290,054.000.0868,088New+$290,054.000.12
Schonfeld Group$267,302.000.0762,747New+$267,302.00<0.01
Beacon Pointe Advisors Llc$255,600.000.0760,0000%+$0<0.01
Two Sigma$233,218.000.0654,746-67.25%-$478,879.46<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.